Kabir Nath

Compass Pathways (NASDAQ:CMPS) has announced delays for two key Phase 3 clinical trials involving its psilocybin program, widely seen as a leader in the psychedelic drug development space. As Endpoint News reported, the unexpected timeline shifts, unveiled in the company's third-quarter earnings...

The American Medical Association (AMA) is expected to issue the first code for psychedelic therapy reimbursement, following the approval of a joint application submitted by MAPS PBC and COMPASS Pathways (NASDAQ: CMPS). On March 3, the AMA published its Panel Actions summary which included the...

This article was originally published on PSYCH and appears here with permission. UK-based COMPASS Pathways (NASDAQ: CMPS) recently published data from its Phase IIb trials, with COMP360 psilocybin therapy for treatment-resistant depression. This follows the release of the design for the...

Psychedelics mental healthcare firm COMPASS Pathways (NASDAQ: CMPS) reported its financial outcomes for the third quarter ended 30 September 2022 and gave an update on its most recent pipeline and business developments. Numbers on 30 September 2022 show: Cash and cash equivalents totaled $...

COMPASS Pathways plc (NASDAQ: CMPS) released financial results for the second quarter 2022 and gave an update on recent progress across its business. Q2 2022 Financial Highlights Net loss for the three months ended 30 June 2022 was $21.0 million, or $0.50 loss per share, compared with $17.5...

Two companies in the psychedelics space have chosen new chief executive officers: COMPASS Pathways (NASDAQ: CMPS) has chosen Kabir Nath, and Small Pharma will be now led by George Tziras. Compass Pathways Adds Kabir Nath On Board Nath will effectively become chief executive officer...